Vetter to expand its secondary packaging service capacity to meet rising demands
The Vetter VSP facility in Ravensburg is being expanded to include state-of-the-art packaging and assembly equipment to meet the growing need for complex secondary packaging services.
Investment will contribute to a one-stop solution approach for customers.
Vetter has announced a major expansion of its secondary packaging capacities as a response to rising customer needs and market demands for complex packaging solutions. The need for expansion is also a result of Vetter’s continuous growth in new filling lines and new lyophilizers, which is driving the need for increased downstream secondary packaging capacity. The project, already underway, is occurring within the second floor of Vetter’s existing Secondary Packaging (VSP) facility and will result in an increase of approximately 32,000 sq ft of new packaging capacity.
The planned undertaking, which is expected to be completed over the next several years, will include new fully-automated packaging lines, space for manual and semi-automated packaging processes and assembly equipment for a wide variety of formats.
The Vetter serialization and aggregation service, which fulfills current requirements and is prepared for future requirements of regulatory authorities, will also be expanded. A highly flexible, state-of-the-art syringe blister line will include safety device assembly and equipment for packaging Japan quality. The addition of new state-of-the-art assembly machines for pens and autoinjectors will allow Vetter to meet a majority of the growing market need for these systems. Because Vetter suppliers for the platform technologies are market leaders with a strong reputation in the market, a large selection of diverse pen and autoinjector types are offered.
“Often we hear from customers that a high level of expertise in the assembly and packaging of pens, autoinjectors and safety devices is critical for their success,” said Bernd Stauss, Senior Vice President Production/Engineering for Vetter. “Vetter has this experience and can offer a one-stop solution, from development to filling to secondary packaging including serialization of products; a service that is greatly appreciated by our customers.”
The demand for integrated solutions is steadily growing. In the future, the pharmaceutical service provider will continue to expand its offering for one-stop-shop solutions - especially in complex areas such as the secondary packaging of end-user friendly devices which support patient safety, convenience and compliance. As a result, Vetter has an eye on the entire product life cycle of its customers with the usual high quality standards.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.